Jounce Therapeutics

Scientist / Scientific Technical Leader, Translational Genomics

Job ID
2021-1243
Category
Research & Development
Job Location
US-MA-Cambridge

Role / Responsibilities

The ideal candidate will oversee laboratory activities for the discovery and evaluation of novel cancer immunotherapeutic candidates. This person will play an integral role in conducting experiments to support pre-clinical and clinical teams, evaluating and implementing new technologies, and supervising junior lab members.

 

Responsibilities:

  • Ensures oversight of the Translational Genomics lab, including directly supervising one scientist.
  • Contributes expertise to experimental design and conducts translationally focused studies to support drug programs.
  • Develops and implements RNA and DNA based technologies and establishes QC metrics for the group.
  • Responsible for the development of assays to be used as potential predictive and pharmacodynamic biomarkers.
  • Responsible for data analysis, documentation of the work, and clear communication of results in group settings.
  • Drives technical innovation within the genomics space across multiple platforms, including single cell genomics and GeoMx.
  • Acts as subject matter expert for clinical application of genomics technologies and analytical tools.
  • Assists with budgeting, forecasting and project coordination for the lab.
  • Facilitates working relationships with CROs to outsource or collaborate on technical development efforts.

Qualifications

  • Bachelors, Master's or Ph.D. degree in Molecular Biology or a related field with 5+ years' relevant laboratory experience, depending upon degree. Strong preference given to candidates with industry experience.
  • Experience in the use of Molecular Genomics techniques, qPCR and 10x Chromium experience is required
  • Ideal candidate will have significant experience in handling FFPE based gene expression technologies with strong understanding of molecular techniques including RNA handling, quantitative PCR, and other gene-expression platforms such a Nanostring, Fluidigm, and next generation sequencing applications.
  • Substantial hands-on experience in isolation and QC metrics for extraction of nucleic acid from human FFPE tumor samples and other specimens including experience with Bio-Analyzer/Fragment analyzer, Qubit, and Nanodrop.
  • Expertise in quantitative (TaqMan) PCR, Fluidigm, Nanostring or similar platforms, 10x Chromium or other single cell techniques, library preparation for NGS applications, cell free nucleic acid techniques and TCR/BCR assays is essential.
  • Excellent organizational skills and oral and written communication skills.
  • Capable of contributing independently as well as provide group leadership and able to thrive in a highly collaborative, fast-paced, team-oriented environment with colleagues from diverse disciplines.
  • Supervisory experience is preferred.

Statement

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the SELECT trial and with Jounce’s broader pipeline. Jounce’s next development stage product candidate, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state. A Phase 1 trial evaluating JTX-8064 is planned to begin enrollment in the fourth quarter of 2020. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com. 

Company Summary

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the SELECT trial and with Jounce’s broader pipeline. Jounce’s next development stage product candidate, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state. A Phase 1 trial evaluating JTX-8064 is planned to begin enrollment in the fourth quarter of 2020. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com

Options

Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
Share on your newsfeed